Tech Titans Investing Millions to Create Genetically Engineered Babies
By Tina Stevens,
CounterPunch
| 12. 11. 2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter Theil and Reddit founder Alexis Ohanian are supplying lavish funds to explore human embryo gene editing and to market “polygenic” (i.e., multi-gene) screening of embryos for quality control.
While their brassy business models boast the goal of eliminating diseases (for which other less risky interventions are available), skeptical experts can sniff an agenda that is peddled more discretely: engineering children to “enhance” traits such as eye color, height, intelligence, and athletic ability. UC Berkeley scientist Fyodor Urnov’s critique is decisive. “These people armed with very poorly deployed sacks of cash are working on “baby improvement,” he said. University of Virginia behavioral geneticist Eric Turkheimer characterized the marketing of unproven probabilistic screening methods as “corporate eugenics.”
Even when disassociated from the eugenic savagery of WWII Nazi Germany, the tech titans’ “techno eugenics” hasten the arrival of bio-entrepreneurially created societies of...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...